The gut microbiome resides in your large intestine and is host to more than 1000 species of bacteria that perform certain important functions from shaping the immune system to influencing metabolism of nutrients to fortifying the intestinal mucosal barrier (gut barrier).
It is important to know the abundances of the bacteria that symbiotically live in the human gastrointestinal tract because imbalances in the gut microbiome may lead to gastrointestinal symptoms, skin conditions, autoimmune disorders, immune system imbalances, and multiple inflammatory disorders.
Vibrant uses a proprietary microarray hybridization technology platform, using the whole-genome data to simultaneously detect over 300 microorganisms with 99% specificity and 98% sensitivity, unheard-of levels of accuracy in the detection of pathogenic microorganisms. Because Vibrant does not use sequencing technology, which is time-consuming and prone to high level so inaccuracy, the Gut Zoomer is the most accurate microbiome test available to aid discerning healthcare providers in the assessment and treatment of gastrointestinal disorders.
The Gut Zoomer report provides you with actionable recommendations that include potential risks for:
- Intestinal permeability (SCFA producing bacteria and tight junction integrity)
- Intestinal disorders (IBS and IBD related bacteria)
- Small Intestinal Bacterial Overgrowth (SIBO)- related bacteria
- Cardiovascularhealth (inflammationinfluencing and TMAO-related bacteria)
- Autoimmune health (celiac, Crohn’s, rheumatoid arthritis, etc)
- Neurological health (MS, Parkinson’s, and more)
- Liver diseases (cirrhosis, hepatitis, cholangitis, and more)
- Metabolic health (Obesity, diabetes, etc)
- Nutrition (Vitamin production, oxalate metabolism)
- Microbiome and hormone connections (Beta-glucuronidase and Beta-glucosidase)
- 67 pathogenic bacteria
- 24 Intestinal parasites
- 8 viruses
- 5 Fungal or yeast species
- 5 worm species
- 6 antibiotic resistance genes measured
and newly added additional markers of functional digestive status:
- Pancreatic elastase 1
- Bile acids
- Cholic acid
- Chenodeoxycholic acid
- Deoxycholic acid
- Lithocholic acid
- Acetic acid
- Butyric acid
- Propionic acid
- Valeric acid
- Total SCFAs
The test performs the most comprehensive analysis available of your intestinal microbiomeecosystem from a simple one-time stool collection. This test examines the complex and intricate relative abundance of each species or genus measured, in relation to the rest of the ecosystem, to provide a unique perspective on the gut microbiome and its connection to disease and inflammation.
The functional digestive analytes aid healthcare providers in determining if deficiencies in digestive enzymes, bile, or other critical metabolites are root causes of gastrointestinal inflammatory symptoms.
The Vibrant Gut ZoomerTM also provides patients with an actionable report that includes dietary recommendations and other natural supplementation like prebiotics, probiotics, and polyphenols.
Only healthcare providers licensed in their state may order laboratory testing.
The Gut ZoomerTM is the most comprehensive gut microbiome test available on the market to clinicians, including over 170 species and genus-level measurements, as well as phylum assessments and two diversity indexes. We also provide recommendations for 35 commonly used probiotic products that may be appropriate based on risks determined by lab test results. Vibrant’s proprietary microchip technology allows for simultaneous detection of DNA from almost 200 species and genera of microorganisms from a one-time collection of stool sample.
- Commensals (including probiotics)
- Akkermansia muciniphila
- Atopobium parvulum
- Bacillus coagulans
- Bacillus subtilis
- Bacteroides caccae
- Bacteroides vulgatus
- Bacteroidetes/Firmicutes ratio
- Bifidobacterium adolescentis
- Bifidobacterium animalis
- Bifidobacterium animalis subsp Lactis
- Bifidobacterium bifidum
- Bifidobacterium breve
- Bifidobacterium brevis
- Bifidobacterium catenulatum
- Bifidobacterium dentium
- Bifidobacterium infantis
- Bifidobacterium lactis
- Bifidobacterium Longum
- Bifidobacterium spp
- Blautia hydrogenotorophica
- Christensenellaceae minuta
- Clostridia clusters IV
- Clostridia clusters XIVa
- Clostridia clusters XVIII
- Clostridiales Family XIV Incertae Sedis
- Clostridium hathewayi
- Clostridium ramosum
- Clostridium symbiosum
- Clotridiales Incertae Sedis IV,
- Desulfovibrio piger
- Dialister invisus
- Eggerthella lenta
- Enterobacter aerogenes
- Enterococcus gallinarum
- Escherichia coli
- Escherichia coli Nissle
- Eubacterium rectale
- Faecalibacterium prausnitzii
- Lactobacillus acidophillus
- Lactobacillus animalis
- Lactobacillus brevis
- Lactobacillus bulgaricus
- Lactobacillus casei
- Lactobacillus fermentum
- Lactobacillus murinus
- Lactobacillus paracasei
- Lactobacillus plantarum
- Lactobacillus reuteri
- Lactobacillus rhamnosus
- Lactobacillus ruminis
- Lactobacillus sakei
- Lactobacillus salivarius
- Methanobrevibacter smithii
- Porphyromonas gingivalis
- Prevotella copri
- Prevotellaceae /Bacteroidetes (P/B)
- Propionibacterium freudenreichii
- Proteus mirabilis
- Roseburia intestinalis
- Ruminococcus bromii
- Ruminococcus gnavus
- Ruminococcus obeum
- Saccharomyces boulardii
- Solobacterium moorei
- Staphylococcus epidermidis
- Staphylococcus pasteuri
- Streptococcus spp
- Streptococcus thermophiles
- Tyzzerella 4
Pathogenic bacteria include:
- Clostridium difficile Toxin A
- Clostridium difficile Toxin B
- Campylobacter spp
- Campylobacter jejuni
- Campylobacter coli
- Campylobacter upsaliensis
- Plesiomonas shigelloides
- Vibrio (parahaemolyticus)
- Enteropathogenic E.coli (EPEC)
- Enterotoxigenic E.coli (ETEC)Lt/St
- E.coli O157
- Shiga-Like Toxin Producing E.coli(STEC)Stx1/Stx2
- Helicobacter pylori
- Vibrio (cholerae)
- Enteroaggregative E.coli(EAEC)
- Klebsiella pneumoniae
- Edwardsiella tarda
- Yersinia enterocolitica
- Vibrio (vulnificus )
- Entamoeba histolytica
- Giardia lamblia
- Cyclospora cayetanensis
- Chilomastix mesnili
- Cyclospora spp.
- Dientamoeba fragilis
- Endolimax nana
- Entamoeba coli
- Pentatrichomonas hominis
- Larval Nematode
- Ascaris lumbricoides
- Strongyloides stercoralis
- Taenia solium
- Blastocystis hominis
- Trichomonas hominis
- Isospora belli
- Dipylidium caninum
- Diphyllobothrium datum
- Trichuris trichina
- Enterobius vermcularis
- Candida albicans
- Candida spp.
- Geotrichum spp.
- Microsporidium spp.
- Rodotorula spp.
- Ancylostoma duodenale
- Necator americanus
- Trichuris trichiura
- Taenia spp.
- Adenovirus F40/41
- Rotavirus A
- Norovirus GI
- Norovirus GII
- Sapovirus I
- Sapovirus II
- Sapovirus IV
- Sapovirus V
- Epstein Barr virus
and antibiotic resistance genes measured include:
- Helicobacter – Clarithromycin
- Helicobacter – Fluoroquinolones
- Universal Microbiota Resistance Genes – b-lactamase
- Universal Microbiota Resistance Genes – Fluoroquinolones
- Universal Microbiota Resistance Genes – Macrolides
- Universal Microbiota Resistance Genes – Vancomycin
Imbalances in your gut microbiome may lead to the following symptoms or conditions:
- Autoimmune conditions
- Inflammatory Bowel Disease (Crohn’s and ulcerative colitis)
- Irritable Bowel Syndrome
- Celiac disease
- Cardiovascular disease
- Metabolic syndrome
- Liver and gallbladder disease
- Neurological disorders
- Mood abnormalities
- Skin rashes (eczema or dermatitis)
- Inflammatory symptoms
- Small intestinal bacterial overgrowth (SIBO)
- Gas and bloating
- Intestinal permeability (‘leaky gut syndrome’)
- Nutrient deficiencies
- Food sensitivities
Should I stop probiotic supplements before taking Vibrant Gut ZoomerTM sample?
The Vibrant Gut ZoomerTM measures microorganism DNA from a person’s stool sample. The results reflect the relative abundance of these microorganisms (bacteria, candida yeast, parasites, worms, and viruses) compared to a reference range at the time of the sample. Thus, if a person is using a probiotic supplement the days/weeks leading up to the sample collection, their sample will reflect the ecosystem as influenced by the probiotics.
Our practitioners usually like to use the Gut ZoomerTM in one of two ways. They will either have the patient remove or discontinue the probiotic for ~2 weeks before sample collection. The sample will then represent a person’s “baseline” microbiome ecosystem and a practitioner can individually recommend probiotic supplementation from baseline. The second strategy would be to run a Gut ZoomerTM about ~one month into probiotic supplement to determine if that particular product is affective for that individual.
Can you tell me about the Gut Zoomer 3.0 technology?
The Gut ZoomerTM is run on a proprietary microarray hybridization technology platform, using whole genome data to simultaneously detect over 300 microorganisms with 99% specificity and 98% sensitivity, unheard of levels of accuracy in the detection of pathogenic microorganisms. Because Vibrant does not use sequencing technology, which is time-consuming and prone to high levels of inaccuracy, the Gut Zoomer is the most accurate microbiome test available to aid discerning healthcare providers in the assessment and treatment of gastrointestinal disorders.
Does this report show all of the bacteria that are growing in my gut?
Over 1,000 microbial species have been identified in the human gastrointestinal tract, and research is still evolving in this area. Of all the bacterial species identified, only a few hundred bacterial species have been associated with potential health outcomes based on existing scientific studies published in peer-reviewed journals. The Vibrant Gut Zoomer measures those species identified as having the greatest impact on health and disease and test over 300 unique taxa of commensal microorganisms, including ~65 pathogenic microorganisms.
Are there other types of bacteria that may be causing symptoms that are not on this report?
The Gut ZoomerTM looks at three different types of dysbiosis:
- dysbiosis caused by a lack of good flora
- an overgrowth of bacteria that could be considered opportunistic
- a lack of diversity in the types of flora found on the sample.
In the process of putting together a clinical history that takes into account your symptoms, the Gut ZoomerTM test provides multiple correlations/risk factors for certain disease states or metabolic abnormalities. Because this type of testing is still an emerging science, it could be that your symptoms are not explained by the bacteria found on the report, however, because the test provides disease and metabolic associations for 300+ bacteria, this is rare.
How are the reference ranges/cut points established for the Gut Pathogens?
For each microorganism tested, a limit of detection is defined. Limit of Detection (LOD) is defined as the lowest concentration of analyte in a sample that can be reliably detected. The LOD is expressed in terms of the CFU/ml or cells/ml or oocysts/ml as per the organism tested. For more information on Vibrant’s proprietary microarray hybridization technology and its accuracy when detecting pathogens, please see this published study in the peer-reviewed journal Gut Pathogens in which we describe our validation process and the unrivaled levels of accuracy we achieve in detecting pathogenic organisms with this method.
How are the reference ranges and abundance scores for commensal microorganisms established?
Reference ranges have been established using a sample cohort of 192 healthy stool samples. The cut-off for the healthy reference range is set between 2.5% and 97.5%, and the high-risk range is set to greater than 97.5%. The healthy reference range for each bacteria is individually determined and available in the Gut Zoomer Commensal Validation report.
Does the Gut Zoomer test for Candida?
Candida is included on the Gut Zoomer pathogen panel
Does the Gut Zoomer test for SIBO?
No. A stool test is never determinate for SIBO, as stool testing evaluates the large bowel microorganism ecosystem and SIBO is a manifestation in the small bowel (SIBO = Small Intestinal Bacterial Overgrowth). However, there is a correlation with an overabundance of certain bacteria that are associated with SIBO. The Gut Zoomer 3.0 has a specific section for these bacteria which includes both hydrogen- and methane-producing bacteria. If SIBO is suspected, the provider should complete an extensive intake and review of symptoms and consider running Vibrant’s IBSSure which includes anti-CdTB and anti-vinculin antibodies,which have a strong positive correlation with positive SIBO diagnosis.
Can this test tell me what probiotic supplement my patient needs?
Probiotics can play a vital role in helping to re-populate and maintain balance of one’s microbiome ecosystem. There is no one size fits all approach for recommending probiotic supplements. Practitioners should individualize recommendations based on patients’ presenting symptoms and degree of dysbiosis.
The Vibrant Gut Zoomer 3.0 provides individualized probiotics recommendations for each disease state association section listed in the report, displayed in the section titled “your level of probiotic organisms”. Vibrant presents a list of commercially available probiotic organisms which clinical literature has demonstrated to be beneficial for the specific disease-state association listed above. These organisms are also measured on the Vibrant Gut Zoomer 3.0 and an individual’s abundance score for each organism is given. These recommendations and results can help a practitioner define an individual probiotic recommendation and protocol.
What should I do if my calprotectin is significantly elevated?
Calprotectin is a marker of inflammation in the gut. Although it is not diagnostic of inflammatory bowel disease, calprotectin can indicate the possibility of Crohn’s disease, chronic ulcerative colitis, and/or the overuse of NSAID medication. If your calprotectin has been found to be elevated on the Gut Zoomer 3.0 test, you may want to schedule a visit with your gastroenterologist.
What should I do if my pancreatic elastase is low?
Pancreatic elastase is low when the tissues of the exocrine pancreas are not producing enough pancreatic elastase and digestive enzymes. This condition is called exocrine pancreatic insufficiency and can occur when the pancreatic ducts are blocked or the pancreatic enzyme producing cells are blocked. It is more often seen in conditions such as pancreatitis and sometimes pancreatic cancer. It is recommended you consider taking a pancreatic enzyme supplement to your regular meals as well as scheduling a visit with your primary care provider or gastroenterologist.
*Note: if you did the Gut Zoomer 3.0 test with a sample of loose stools/diarrhea, your pancreatic elastase value may be reduced if you do not include any solid stool components.
Autism and the Gut Microbiome https://wp.me/p7lkN2-Q
What is the Gut Microbiome? Why is it Important to Your Health? https://wp.me/p7lkN2-4w
The Gut MicrobiomeandtheEstrobolome: How gut microbesaffectestrogenmetabolism https://vibrantwellnessblog.wordpress.com/2019/10/08/the-gut-microbiome-and-the-estrobolome-how-gut-microbes-affect-estrogen-metabolism
Don’tjudge a bookbyitscover: Are harmfulbacteriamasqueradingas “goodguys” in your gut? https://vibrantwellnessblog.wordpress.com/2019/09/23/dont-judge-a-book-by-its-cover-are-harmful-bacteria-masquerading-as-good-guys-in-your-gut
The Link BetweenYour Gut HealthandCholesterol https://vibrantwellnessblog.wordpress.com/2019/09/16/the-link-between-your-gut-health-and-cholesterol
Short-Chain FattyAcidsandthe Intestinal Barrier https://vibrantwellnessblog.wordpress.com/2019/07/22/short-chain-fatty-acids-and-the-intestinal-barrier
Gut Microbiome and leaky gut
Enterobacteriaceae Kim K. A., Gu W., Lee I. A., Joh E. H., Kim D. H. (2012). High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway.
The Study investigated the effect of endotoxin-induced inflammation at both systemic and intestinal levels in response to a high-fat diet (HFD). The below following observations were seen in the HFD mice reduction in the expression of tight junction-associated proteins claudin-1 and occludin in the colon, induced the growth of Enterobacteriaceae and the production of endotoxin and induced macrophage infiltration and inflammation in the adipose tissue, as well as an increase in the circulating proinflammatory cytokines.
Bacteroides, Bifidobacterium, Propionibacterium, Eubacterium, Lactobacillus, Clostridium, Roseburia, Prevotella Macfarlane G. T., Macfarlane S. (2012). Bacteria, colonic fermentation, and gastrointestinal health.
This review summarizes the role of short-chain fatty acid (SCFA) in energy metabolism in large intestine, starting from the fermentation by the gut microbiota to the uptake by the colon and ending with the effects on gastrointestinal health. Bacteroides are one of the major species involved in the production of the SCFA acid, Acetate which plays an important physiological role in immune system, anti-carcinogenesis, increase colonic blood flow and adipogenesis.
Everard A., Belzer C., Geurts L., Ouwerkerk J. P., Druart C., Bindels L. B., et al. . (2013).Cross-talk between Akkermansiamuciniphila and intestinal epithelium controls diet-induced obesity.
This study aims demonstrate the link between the obesity and type 2 diabetes with the altered gut microbiota. Result indicates a significant contribution from species Akkermansiamuciniphila which seen in decreased amount in genetically and diet-induced obese and type 2 diabetic mice .Furthermore the study demonstrated that prebiotic (oligo fructose) treatment restored A. muciniphila abundance and improved gut barrier and metabolic parameters in obese mice.
Lactobacillus reuteri, Lactobacillus rhamnosus Rosenfeldt V., Benfeldt E., Valerius N. H., Paerregaard A., Michaelsen K. F. (2004).
A total of 41 children with moderate and severe atopic dermatitis completed a 6 week randomized, double-blind,placebo-controlled, crossover study. Subjects were given Lactobacillus supplements containing (L. rhamnosus and L. reuteri). Result showed a significant decrease in gastrointestinal symptoms over the period of the study with the probiotic treatment.
Gut Microbiome and Intestinal Health Dorea, Ruminococcus Rajili-Stojanovi M1, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome.
The microbiota composition was assessed by global and deep molecular analysis of fecal samples from 62 patients with IBS patients and 46 healthy individuals (controls). Result indicated that the intestinal microbiota of IBS patients have a 2 fold increase in number of Dorea, Ruminococcus, and Clostridium.
Lachnospira, Phascolarctobacterium Xochitl C Morgan, Timothy L Tickle, Harry Sokol, Dirk Gevers, Kathryn L Devaney, Doyle V Ward, Joshua A Reyes, Samir A Shah, Neal LeLeiko, Scott B Snapper, Athos Bousvaros, Joshua Korzenik, Bruce E Sands, Ramnik J Xavier and Curtis Huttenhower.
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment”. We analyzed the microbiota of intestinal biopsies and stool samples from 231 IBD and healthy subjects by 16S gene pyrosequencing and followed up a subset using shotgun metagenomics.Result indicated Inflammatory bowel diseases (IBD) Crohn’s disease (CD), proportions of the Clostridia are altered: the Roseburia and Faecalibacterium genera of the Lachnospiraceae and Ruminococcaceae families are decreased, whereas Ruminococcusgnavus increased.
Desulfovibriopiger Loubinoux J, Bronowicki JP, Pereira IA, Mougenel JL, Faou AE Sulfate-reducing bacteria in human feces and their association with inflammatory bowel disease.
Sulfate-reducing bacteria were isolated from 10 healthy individuals (24%), 15 patients presenting with inflammatory bowel diseases (68%), and 33 patients with other symptoms (37%). The prevalence of D. piger was significantly higher in inflammatory bowel disease patients (55%) as compared to healthy individuals (12%) or patients with other symptoms (25%) (P < 0.05).
CoprococcusEuctatus Kassinen, A., Krogius-Kurikka, L., Makivuokko, H., Rinttil, T.Paulin, L., Corander, J., Malinen, E.,Apajalahti, J. &Palva, A. The fecal microbiota of irritable bowel syndrome patients differs significantlyfrom that of healthy subjects.
Microbial genomes from fecal samples of 24 patients with IBS and 23 controls were collected and analyzed. Coprococcuseutactus species were significantly decreased in all IBS subtypes (IBS-C, IBS-D) compared with the healthy controls samples.
Lactobacillus, Veillonella, Ruminococcusproductus, Bifidobacterium, catenulatum, Malinen E, Rinttila T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR.
Fecal Samples of 27 IBS patients were compared with 22 control subjects to extensively analyze the intestinal microbes in IBS. Extensive individual variation was observed in GI microbiota among both IBS and control group, furthermore Result indicated a lower amount of lactobacillus in the samples of diarrhea predominant IBS patients.
Gut Microbiome and Cardiovascular Health Collinsella, Eubacterium Karlsson FH, Fåk F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, Bäckhed F, and Nielsen J Symptomatic atherosclerosis is associated with an altered gut metagenome.
The patient samples were from the Goteborg atheroma study group biobank, which includes sample from patients who had undergone surgery to excise an atherosclerotic plaque. All sample were sequenced in the Illumina HISeq2000 instrument,the finding shows an increased amount of Collinsella in cardio vascular patients having relative abundance score >0.015 compared to the control group having lesser than 0.005.
Prevotella, Sporobacter, Peptostreptococcaceae, Peptostreptococcaceaeincertaesedis, Clostridiaceae, Fusibacter, Lachnospira, Clostridium, ClostridialesIncertae Sedis XII R A Koeth et al.Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
The study links the contribution of intestinal microbiota towards the L-carnitine, a nutrient in red meat with the increased risk of cardiovascular disease. Based on the result they hypothesized that the dietary l-carnitine in humans, like choline and phosphatidylcholine, might be metabolized to produce TMA and TMAO in a gut microbiota–dependent fashion and be associated with atherosclerosis risk. The major gut microbiota contributed to increase levels of TMAO levels in CVD patients were Prevotella, Sporobacter, Peptostreptococcaceae and Peptostreptococcaceaeincertaesedis, Clostridiaceae, Fusibacter, Lachnospira, Clostridium and ClostridialesIncertaeSedis XII.
Anaerococcus hydrogenalis, Clostridium asparagiforme, Clostridium hathewayi T. Liu et al.Intestinal Microbiota Metabolism and Atherosclerosis.
Study details the link between cardiovascular disease and TMAO. It has been observed that several TMA-containing compounds may be catabolized by specific intestinal microbiota, resulting in TMA release which then converted into TMAO in liver.The major intestinal microbiota contributed to increase levels of TMAO levels were Anaerococcushydrogenalis,Clostridium asparagiforme, Clostridium hathewayi.
Gut Bacteria and Autoimmune Health Helicobacter Lebwohl B, Blaser MJ, Ludvigsson JF, Green PH, Rundle A, Sonnenberg A, Genta RM “Decreased risk of celiac disease in patients with Helicobacter pylori colonization.
In a study consisting of 136,179 patients, atotal of 2,689 (2.0) % had celiac disease and Helicobacter pylori prevalence was significantly lower in patients with CD (4.4%) than in those without CD (8.8%) with the odd ratio of 0.48.
Aggregatibacter, Porphyromonas Luigi Nibali, Brian Henderson, Syed Tariq Sadiq, and Nikos Donos Genetic Dysbiosis: the role of microbial insults in chronic inflammatory diseases.
A recent survey in an US adult population of 3,742 individuals revealed a prevalence of 47% for periodontitis. Periodontopathogenic bacteria include gram-negative bacteria such as Aggregatibacteractinomycetemcomitans, Porphyromonasgingivalis and Tannerella forsythia.
These bacteria are thought be able to enter the bloodstream through infected periodontal, have been found in
atheromatous plaques, amniotic fluid of pregnant women and are thought to initiate rheumatoid arthritis in
Dialister Joossens M1, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, Vandamme P, Vermeire S Dysbiosis of the fecal microbiota in patients with Crohn’s disease and their unaffected relatives.
Focusing on families with at least three members affected with CD, fecal samples of 68 patients with Crohn’s
disease (CD), 84 of their unaffected relatives and 55 matched controls were subjected to community fingerprinting of the predominant microbiota using denaturing gradient gel electrophoresis (DGGE). Results suggests that there is a decrease in Dialisterinvisus (p=0.04) in positive CD patients compared to the control group.
Prevotella GangweiOu , MD, PhD , Maria Hedberg , PhD , Per H ö rstedt , PhD , Vladimir Baranov , MD, PhD , G ö teForsberg , MD, PhD , MirvaDrobni , PhD , Olof Sandstr ö m , MD, PhD , Sun Nyunt Wai , MD, PhD ,IngegerdJohansson , OD, PhD , Marie-Louise Hammarstr ö m , PhD , OlleHernell , MD, PhD and Sten Hammarstr ö m , PhD “Proximal Small Intestinal Microbiota and Identification of Rod-Shaped Bacteria Associated With Childhood Celiac Disease.
45 children with CD and 18 clinical controls were studied. s. The proximal small intestine microbiota in biopsies from CD patients collected during 2004 – 2007 differed only marginally from that of controls, and only one biopsy (4 % ) had rod-shaped bacteria by SEM (SEM + ). In nine frozen SEM +CD biopsies from the previous study, microbiotas were significantly enriched in Clostridium,Prevotella, and Actinomyces compared with SEM biopsies. Bacteria of all three genera were isolated from children born during the Swedish CD epidemic. New Clostridium and Prevotella species and Actinomyces graevenitzii were tentatively identified.
Gut Microbiome and Metabolic Health Lactobacillus Reuteri,Lactobacillus paracasei,Bifidobacterium Animalis,Methanobrevibacter smithii M Million, E Angelakis, M Maraninchi, M Henry, R Giorgi4, R Valer, B Vialettes and D Raoult, “Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibactersmithii and Escherichia coli.
263 individuals, including 134 obese, 38 overweight, 76 lean and 15 anorexic were subjects to test for the correlation between bacterial concentration and body mass index (BMI). M. smithii was found in 63% of individuals. The fecal concentration of Methanobrevibactersmithii OR= 0.43 were negatively associated with the BMI.
Julia K. Goodrich, Jillian L. Waters, Angela C. Poole, Jessica L. Sutter, OmryKoren, Ran Blekhman,Michelle Beaumont, William Van Treuren, Rob Knight, Jordana T. Bell, Timothy D. Spector, Andrew G.Clark, and Ruth E. Ley
Human genetics shape the gut microbiome”. In a study consisted of microbiotas across > 1,000 fecal samples obtained from the Twins UK population, including 416 twin-pairs. Results indicates an increase in Oscillospira in lean subjects compared to high BMI candidates.
Junjie Qin, Yingrui Li, and Zhiming Cai et.al “A metagenome-wide association study of gut microbiota in type 2 diabetes
A two-stage case-control metagenome-wide association study (MGWAS) was developed based on deep next generation shotgun sequencing of DNA extracted from the stool samples from a total of 345 Chinese T2D patients and non-diabetic controls. Using the taxonomic characterization from these MLGs, it was found that almost all of the MLGs enriched in the control samples were from various butyrate producing bacteria,including Roseburia intestinalis and Roseburiainulinivorans.
Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W,Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M,Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M,LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J,Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J “A metagenome-wide association study of gut microbiota in type 2 diabetes.
The gut microbial content in patients (345 Chinese individuals) with type 2 diabetes were analyzed through deep shotgun sequencing method. MGWAS analysis showed that patients with type 2 diabetes were characterized by a moderate degree of gut microbial Dysbiosis amongst which Eggerthella species had an OR of 1.57.
Gut Microbiome and Nutrition Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium breve,Bifidobacterium adolescentis LeBlanc et al.Bacteria as vitamin suppliers to their host: a gut microbiota perspective.
In humans it has been shown that members of the gut microbiota are able to synthesize vitamin K as well as most of the watersoluble B vitamins, such as biotin, cobalamin, folates, nicotinic acid, panthotenic acid, pyridoxine, riboflavin and thiamine. The study shows that some species of Bifidobacterium such as Bifidobacterium bifidum, B.Longum, B.Breve, B.adolescentis are claimed to be the key components to exhibit the vitamin production.
Bifidobacterium animalis subspecies lactis
Turroni et al. Oxalate-Degrading Activity in Bifidobacterium animalis subsp. lactis: Impact of Acidic Conditions on the Transcriptional Levels of the Oxalyl Coenzyme A (CoA) Decarboxylase and Formyl-CoA Transferase Genes.
Intestinal oxalate degrading bacteria plays an important role in maintaining oxalate homeostasis and reducing the risk of kidney stones. In this study, the oxalate degradation activities of 14 species of Bifidobacterium strains were examined, among which results indicates B. animalis carries the oxc gene, which encodes oxalyl-coenzyme A (CoA) decarboxylase, a key enzyme in oxalate catabolism which then making it a strong candidate for the prophylaxis and management of oxalate-related kidney disease.
Methanobrevibacter smithii Mark Pi mentel MD, Robert P Gunsalus, Satish SC Rao MD and Husen Zhang Methanogens in Human Health and Disease.
The review examines the impact of methanogens in human health and disease.Methanobrevibactersmithii accounts for 94% of the methanogen population. Methanogens oxidize hydrogen to produce methane and ensure more complete fermentation of carbohydrate substrates, leading to higher production and adsorption of short-chain fatty acids, which may lead to obesity. Recent evidence has linked methane production to the pathogenesis of constipation and irritable bowel syndrome (IBS), as well as obesity.